BioMarin Pharmaceutical is searching for a new chief financial officer following Dan Spiegelman’s exit last week, Forbes reports.
The executive’s exit comes as the drugmaker is working to release what would be the world’s costliest gene therapy to treat Hemophilia A, Valrox.
“I would like to thank Dan for his important contributions and leadership during his tenure at the company,” BioMarin CEO Jean-Jaques Bienaimé said in a statement. “Over the last seven and a half years, he has played an invaluable role in supporting the company’s growth.”
According to the report, Spiegelman will remain with the company until September to facilitate a smooth transition.
To read the full report on Forbes, click here.